- Home
- KFFB vs MREO Comparison
KFFB vs MREO Comparison
Compare KFFB & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KFFB | MREO |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United Kingdom |
| Employees | 59 | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.0M | 50.3M |
| IPO Year | 2004 | 2017 |
Fundamental Metrics
Financial Performance| Metric | KFFB | MREO |
|---|---|---|
| Price | $5.57 | $0.31 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 4.4K | ★ 4.8M |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 109.52 | 16.67 |
| EPS | ★ 0.15 | N/A |
| Revenue | $15,000.00 | ★ $500,000.00 |
| Revenue This Year | N/A | $5,184.20 |
| Revenue Next Year | N/A | $55.51 |
| P/E Ratio | $37.37 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.01 | $0.20 |
| 52 Week High | $5.65 | $2.37 |
Technical Indicators
Market Signals| Indicator | KFFB | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 56.05 | 51.43 |
| Support Level | $4.23 | $0.29 |
| Resistance Level | $5.48 | $0.35 |
| Average True Range (ATR) | 0.10 | 0.03 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 51.72 | 45.19 |
Price Performance
Historical ComparisonAbout KFFB Kentucky First Federal Bancorp
Kentucky First Federal Bancorp is a holding company. The company, through its subsidiaries, is engaged mainly in the business of accepting deposits from the general public and using such funds to originate loans secured by first mortgages on owner-occupied, residential real estate and other loans secured by real estate. Its primary products and services include Residential mortgage loans, Multi-family loans, Construction loans, and types of deposits etc. The company mainly operates in Perry, Franklin, Boyle, and Garrard and surrounding counties in Kentucky, USA.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).